News | August 12, 2021
Indian pharma market grew by 13.7% in July 2021: Ind-Ra
Demand normalisation post the second wave contributed to the steady growth
Demand normalisation post the second wave contributed to the steady growth
The profits were bolstered by the Boehringer Ingelheim MEK program income
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
The company expects revenue growth of 10-15 per cent in the US
India business contributes to a stellar performance
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Adjusted PAT declined 18.8% YoY
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Jubilant announced the completion of demerger of pharma and LSI business into two separate companies
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
